HKSE - Delayed Quote HKD

Abbisko Cayman Limited (2256.HK)

Compare
4.820
0.000
(0.00%)
At close: January 28 at 12:08:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
19,060.000
19,060.000
--
22,682.000
--
Gross Profit
19,060.000
19,060.000
--
22,682.000
--
Operating Expense
508,960.000
508,960.000
486,644.000
336,822.000
146,530.000
Operating Income
-489,900.000
-489,900.000
-486,644.000
-314,140.000
-146,530.000
Net Non Operating Interest Income Expense
63,323.000
63,323.000
32,333.000
15,979.000
10,936.000
Pretax Income
-431,583.000
-431,583.000
-495,606.000
-1,809,993.000
-706,639.000
Net Income Common Stockholders
-431,583.000
-431,583.000
-495,606.000
-1,809,993.000
-706,639.000
Diluted NI Available to Com Stockholders
-431,583.000
-431,583.000
-495,606.000
-1,809,993.000
-706,639.000
Basic EPS
-0.67
-0.67
-0.80
-7.71
-1.01
Diluted EPS
-0.67
-0.67
-0.80
-7.71
-1.01
Basic Average Shares
647,226.272
647,226.272
620,675.952
234,883.376
702,466.350
Diluted Average Shares
647,226.272
647,226.272
620,675.952
234,883.376
702,466.350
Rent Expense Supplemental
725.000
725.000
1,351.000
--
--
Total Expenses
508,960.000
508,960.000
486,644.000
336,822.000
146,530.000
Net Income from Continuing & Discontinued Operation
-431,583.000
-431,583.000
-495,606.000
-1,809,993.000
-706,639.000
Normalized Income
-432,289.000
-432,289.000
-495,606.000
-1,815,893.000
-706,805.000
Interest Income
65,493.000
65,493.000
35,018.000
16,938.000
11,274.000
Interest Expense
2,170.000
2,170.000
2,685.000
959.000
338.000
Net Interest Income
63,323.000
63,323.000
32,333.000
15,979.000
10,936.000
EBIT
-429,413.000
-429,413.000
-492,921.000
-1,809,034.000
-706,301.000
EBITDA
-410,991.000
-410,991.000
-477,123.000
-1,797,148.000
-696,810.000
Reconciled Depreciation
18,422.000
18,422.000
15,798.000
11,886.000
9,491.000
Net Income from Continuing Operation Net Minority Interest
-431,583.000
-431,583.000
-495,606.000
-1,809,993.000
-706,639.000
Total Unusual Items Excluding Goodwill
706.000
706.000
--
5,900.000
166.000
Total Unusual Items
706.000
706.000
--
5,900.000
166.000
Normalized EBITDA
-411,697.000
-411,697.000
-477,123.000
-1,803,048.000
-696,976.000
12/31/2020 - 10/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1530.HK 3SBIO
6.010
-3.22%
 
ADAG Adagene Inc.
1.9000
+2.70%
 
2269.HK WuXi Biologics (Cayman) Inc.
18.420
-0.22%
 
KYMR Kymera Therapeutics, Inc.
39.59
-2.13%
 
NUVB Nuvation Bio Inc.
2.3100
-3.75%
 
RPRX Royalty Pharma plc
31.58
-0.03%
 
LXRX Lexicon Pharmaceuticals, Inc.
0.7562
-7.71%
 
XFOR X4 Pharmaceuticals, Inc.
0.7001
+5.74%
 
DNA Ginkgo Bioworks Holdings, Inc.
13.36
-3.95%